20161005-ov-vancouver-vacv-antibody-poster-final-us
Category: 2016
Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
20160905 – H1 update – EN – V10
Transgene Announces Participation at Upcoming Investor Events
20160901 – Next investor events – EN
Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee
20160721 – Safety TG1050 EN Vdef
Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene
Marine Ricordel, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor
Anita Spindler, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
Johann Foloppe, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Ghassan K. Abou-Alfa, et al. ASCO Annual Meeting 2016, June 3-7, 2016, Chicago Illinois Download the poster here Poster Presentation
Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy
20160531 – ASCO_Poster_PR_V2_clean
Composition of the Board of Directors and Statutory Auditors
20160525 – nomination Mr Beret – us